Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

NCT ID: NCT06718738

Last Updated: 2024-12-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-15
• Study Completion Date: 2026-08-15

Brief Summary

This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer

Detailed Description

This study is planned to enroll 6-12 patients with advanced colorectal cancer, using a modified "3+3" design for dose escalation, with two dose groups of 12×10^8 CAR-T cells and 20×10^8 CAR-T cells. 3-6 subjects are planned to be enrolled in each dose group to assess their safety, and if the incidence of horizontal dose-limiting toxicity (DLT) is ≤1/6 within 28 days after transfusion in one dose group, the next dose group can be started. If the incidence of horizontal dose-limiting toxicity (DLT) in a dose group is ≤1/6 within 28 days after transfusion, transfusion of cells from the next dose group can be initiated.

This study will be divided into a screening period, a cell collection period, a chemotherapy pretreatment period, a return infusion and a follow-up period, and within 28 days of return infusion the investigator will assess whether a DLT (Dose limited toxicity) event has occurred to confirm the safety of this dose group.

Conditions

Colorectal Cancer (CRC)

Keywords

Advanced colorectal cancer; IM96 CAR-T

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IM96 CAR-T Cells

After preconditioning with chemotherapy, IM96 CAR-T Cells will be evaluated

Group Type: EXPERIMENTAL

IM96 CAR-T Cells

Intervention Type: BIOLOGICAL

IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

Interventions

IM96 CAR-T Cells

IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. The age is 18 to 75 years (including boundary values) and the gender is not limited;

2. Patients with advanced GI tumors diagnosed by pathohistology, mainly:

(1)Patients with metastatic colorectal cancer who have failed or are intolerant to second-line and above standard therapy;

Notes:

1. The standardized systemic treatment received by the patient must be in accordance with the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Treatment of Colorectal and Gastric Cancer, 2024 Edition;

2. Claims of treatment intolerance: Patients who are unable to continue current effective systemic standardized treatment due to toxic side effects such as grade ≥3 vomiting, diarrhea, abdominal pain, bone marrow suppression, etc., and who do not accept refusal for financial and personal reasons; 3.Presence of at least one measurable lesion that meets RECIST 1.1 criteria; 4.Patients must provide a tumor sample within 2 years that meets the requirements (paraffin block or number of unstained sections that meet the testing requirements set by the Institute) that is positive for GUCY2C expression by immunohistochemistry; 5.Survival is expected to be more than 3 months; 6.Eastern cooperative oncology group (ECOG) score of 0-1 (refer to Attachment 2); 7.Women of childbearing potential who have a negative blood pregnancy test prior to the start of the trial and who agree to use effective contraception during the trial and up to the last follow-up visit; male patients whose partners are of childbearing potential agree to use effective contraception during the trial and up to the last follow-up visit 8.Laboratory tests should meet at least the indicators specified below:

1. Hemoglobin (Hb) ≥ 90 g/L;

2. Neutrophil count (Absolute neutrophil count, ANC) ≥ 1.5 x 10^9/L;

3. Platelet count (PLT) ≥ 75 x 10^9/L;

4. Absolute lymphocyte value ≥ 0.6 x 10^9/L;

5. Lymphocytes make up ≥10% of white blood cells;

6. Creatinine clearance ≥60 ml/min;

7. Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 x ULN and total bilirubin (TBL) ≤ 1.5 x ULN (for elevations of ALT and AST that can be explained by hepatic aggression, the high limits for AST and ALT can be adjusted upward to 5-fold, and the high limit for TBL may be adjusted upward to 3-fold;

8. Serum albumin ≥ 3.0 g/dL.

9. Prolongation of prothrombinogen time ≤ 4s; 9.Left ventricular ejection fraction ≥ 50% with a normal ECG or an abnormal ECG that, in the judgment of the investigator, does not require treatment; 10.Oxygen saturation >92% in non-oxygenated state; 11.Vascular access is adequate for cell collection, and lines are available for patients with existing central venous catheters; Those who voluntarily participate in the trial and sign the informed consent form

Exclusion Criteria

1. Presence of brain metastases;

2. Patients who have previously received or are awaiting an organ transplant;

3. Toxicity due to prior therapy not stabilized or recovered to ≤ grade 1 (except in cases judged by the investigator to be not clinically significant);

4. Plasmapheresis (e.g., pleural effusion, abdominal effusion, pericardial effusion) with symptoms of compression that cannot be controlled with treatment;

5. Autoimmune disease requiring systemic immunosuppressive therapy (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) within 2 years prior to the start of screening;

6. Presence of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and clinically significant pulmonary function test abnormalities;

7. Use of any of the following medications or treatments during the designated time period prior to cell collection:

1. Therapeutic doses of corticosteroids have been used within 7 days prior to cell collection. However, topical and inhaled steroids are permitted;

2. Received chemotherapeutic agents within 1 week prior to cell collection. Enrollment was allowed if the oral chemotherapeutic drug had passed at least 3 half-lives prior to cell collection;

3. Those who used drugs to stimulate bone marrow hematopoietic cell production within 5 days prior to cell collection;

4. Use of study drug within 4 weeks prior to cell collection. However, enrollment was allowed if the trial treatment was ineffective or the disease progressed during the trial and at least 5 half-lives had elapsed prior to cell collection;

5. Received interventional therapy, radiotherapy, ablation, and other localized treatments for the study disease within 4 weeks prior to cell collection;

6. Patients who have had major surgery or significant trauma within 4 weeks prior to cell collection or who are expected to require major surgery during the study period;

7. Received treatment with targeted agents such as regorafenib, furaquintinib, etc. within 1 week prior to cell collection;

8. Prior treatment with anti-GUCY2C target (unless GUCY2C target test remains positive);

9. Those who have received other cell therapy or genetically modified cell therapy in the past, such as TCR-T therapy, CAR-T therapy, etc;

10. If immunotherapy such as anti-PD1 and PD-L1 has been used prior to IM96 CAR-T cell transfusion, at least 5 half-lives must have elapsed after the last dose and before IM96 CAR-T cell transfusion;

11. Prior or clinically significant CNS disorders at screening, such as epilepsy, epileptic seizures, cerebrovascular disease (ischemia/hemorrhage/cerebral infarction), cerebral edema, reversible posterior leukoencephalopathy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, or psychiatric disorders;

12. Chronic or active infection requiring systemic therapy and history of symptomatic viral infection that has not been completely cured. For example, Hepatitis B: patients who are positive for Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) and whose peripheral blood HBV-DNA test is above the lower limit of detection; patients who are positive for Hepatitis C Virus Antibody (HCVAb) and whose peripheral blood HCV-RNA test is above the lower limit of detection; and patients infected with Human Immunodeficiency Virus (HIV), Syphilis;

13. Active EBV and cytomegalovirus, defined as patients with IgM antibody-positive or IgM antibody-negative but higher-than-normal EBV-DNA in EBV serum; and cytomegalovirus (CMV) seropositive or IgM antibody-negative but higher-than-normal CMV-DNA in serum;

14. Vaccination with live vaccine within 6 weeks prior to the start of screening;

15. Abnormalities of cardiac function include: long QTc syndrome or QTc interval >480 ms; complete left bundle branch block, degree II/III AV block; severe, uncontrolled arrhythmias requiring pharmacologic therapy; history of chronic congestive heart failure with NYHA class ≥3 (refer to Attachment 3) with a cardiac ejection fraction of less than 50% in the 6 months prior to screening; CTC AE ≥3 grade heart valve disease; myocardial infarction, cardiac angioplasty or stenting, unstable angina, history of severe pericardial disease, or other clinically significant cardiac disease within 6 months prior to screening;

16. Patients requiring anticoagulation therapy;

17. Requires long-term use of medications that can affect clotting (e.g., aspirin, warfarin, etc.);

18. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to initiation of screening;

19. Other untreated malignant tumors within the previous 5 years or concurrently, except cervical cancer in situ, basal cell carcinoma of the skin, and ductal carcinoma in situ of the breast;

20. Infections (fungal, bacterial, viral, or other) that require intravenous antimicrobial control or are uncontrollable, for simple urinary tract infections, and for bacterial pharyngitis, may be enrolled if the investigator evaluates that they can be controlled by curative treatment;

21. Patients with digestive tract obstruction;

22. Patients at high risk for bleeding or perforation;

23. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study; The presence of any factors affecting compliance with the protocol or the patient's unwillingness or inability to comply with the procedures required in the study protocol, as determined by the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Cancer Hospital & Institute

OTHER

Sponsor Role: collaborator

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lin Shen, PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Fei Wu

Role: CONTACT

Phone: 8615801390058

Email: wufei@imunopharm.com

Lin Shen, PhD

Role: CONTACT

Phone: 8610 88196561

Email: doctorshenlin@sina.cn

Facility Contacts

Lin Shen, PhD

Role: primary

Other Identifiers

YMSZ9601

Identifier Type: -

Identifier Source: org_study_id